BioCentury
ARTICLE | Company News

Omeros seeks approval for OMS302

August 2, 2013 12:41 AM UTC

Omeros Corp. (NASDAQ:OMER) submitted an NDA to FDA for use of OMS302 in patients undergoing intraocular lens replacement surgery. The company plans to submit an MAA to EMA this quarter. The product is a combination of the anti-inflammatory agent ketorolac and the pupil dilating agent phenylephrine. ...